Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

on behalf of CARMELINA® investigators

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk'. Together they form a unique fingerprint.

Medicine & Life Sciences